联合应用依折麦布对他汀治疗冠心病患者血脂达标率的影响

程姝娟; 颜红兵; 马芹; 徐方兴

Abstract

程姝娟,颜红兵,马芹,徐方兴.联合应用依折麦布对他汀治疗冠心病患者血脂达标率的影响[J].Chinese journal of Epidemiology,2009,30(6):631-632

联合应用依折麦布对他汀治疗冠心病患者血脂达标率的影响

Effectiveness of ezetimibe in improving lipid goal attainment in patients with coronary heart diseases treated with statin

Received:May 08, 2009

DOI：

KeyWord: 血脂异常依折麦布他汀

English Key Word: Dislipidemia Ezetimibe Statin

FundProject:

Author Name	Affiliation	E-mail
CHENG Shu-juan	Beijing Anzhen Hospital Affiliated to the Capital University of Medical Science, Beijing 100029, China
YAN Hong-bing	Beijing Anzhen Hospital Affiliated to the Capital University of Medical Science, Beijing 100029, China	yan591204@yahoo.com.cn?
MA Qin	Beijing Anzhen Hospital Affiliated to the Capital University of Medical Science, Beijing 100029, China
XU Fang-xing	Beijing Anzhen Hospital Affiliated to the Capital University of Medical Science, Beijing 100029, China

Hits: 3938

Download times: 1500

Abstract:

目的观察联合依折麦布对单独应用他汀类药物未能使低密度脂蛋白胆固醇(LDL-C)达标的冠心病合并糖尿病患者血脂的影响.方法 61例应用他汀治疗12周后LDL-C未达标(<2.07mmol/L)的冠心病合并糖尿病患者,在原用药基础上联合应用依折麦布(10mg/d),观察治疗8周后的血脂水平,及对丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转氨酶(AST)及肌酸激酶(CK)的影响.结果干预前LDL-C未达标的61例患者LDL-C分别为(2.74±0.43)nmaol/L和(2.19±0.32)mmol/L(P=0.03);干预后LDL-C水平下降20.1%(P<0.05),总胆固醇(TC)下降19.1%(P<0.05),LDL-C水平达标率为74%(45/61).干预前后甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)无显著变化(P>0.05),AST、ALT和CK等指标也无显著变化(P>0.05).结论联合应用依折麦布可以提高他汀类药物治疗冠心病合并糖尿病患者的LDL-C达标率,使LDL-C水平进一步降低.

English Abstract:

Objective To investigate the efficacy and safety of ezctimibe on uncontrolled LDL-C when added to ongoing statin therapy in patients with coronary heart diseases (CHD) and diabetes mellitus (DM). Methods 61 patients with LDL-C level exceeding target goal (<2.07 mmol/L) after 12 weeks' treatment with statins, received ezetimibe in addition to their ongoing statin therapy for 8 weeks. Lipid parameters, alanine aminotransferase(ALT), aspartic aminotransferase(AST) and ereatine kinase(CK) were compared before and after the adding of ezetimibe. Results LDL-C before and after the adding of ezetimibe was (2.74±0.43) mmol/L and (2.19±0.32) mmol/L, respectively (P=0.03) in 61 patients. Ezetimibe added to statin therapy significantly reduced the LDL-C level and TC level by additional 20.1% and 19.1%, respectively (P<0.05). 74%(45/61) patients treated with ezetimibe added to statin reached their target LDL-C goal. No change of TG and HDL-C was observed and no change of AST, ALT and CK was found either. Conclusion Ezetimibe added to statin therapy lowered LDL-C level further and improved the goal attainment in patients with CHD and DM.

View Fulltext Html FullText View/Add Comment Download reader